Illumina appointed Dr. Daniel M. Skovronsky, Chief Scientific and Product Officer at Eli Lilly, to its Board of Directors. His expertise in drug discovery and clinical development aligns with Illumina's focus on genomics and multiomics innovation. This move aims to strengthen Illumina's leadership in precision medicine and genomic technologies. Dr. Skovronsky's background includes leading Lilly's global R&D and founding a biotech company, adding valuable scientific and strategic insight to Illumina's board.

More News (ILMN)

Ovarian cancer diagnostics market to reach $8.08B by 2035, driven by AI and biomarker testing advances.

The global ovarian cancer diagnostics market is projected to grow from $4.92 billion in 2025 to $8.08 billion by 2035, at a CAGR of 5.06%. Growth is fueled by rising ovarian cancer cases, increased adoption of AI-powered imaging, biomarker testing, a...

Market News

Bullish

4 days ago